Who are Galantamine (Reminyl)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Galantamine-CR, Placebo/Galantamine (Reminyl®), Extended-release galantamine hydrobromide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/galantamine-reminyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Galantamine (Reminyl) — Competitive Intelligence Brief

Galantamine (Reminyl) (Galantamine (Reminyl)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholinesterase inhibitor with nicotinic receptor modulation. Area: Neurology.

marketed Acetylcholinesterase inhibitor with nicotinic receptor modulation Acetylcholinesterase; nicotinic acetylcholine receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Galantamine (Reminyl) (Galantamine (Reminyl)) — Janssen-Cilag Pty Ltd. Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, and also acts as an allosteric modulator of nicotinic receptors to enhance cholinergic neurotransmission.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Galantamine (Reminyl) TARGET	Galantamine (Reminyl)	Janssen-Cilag Pty Ltd	marketed	Acetylcholinesterase inhibitor with nicotinic receptor modulation	Acetylcholinesterase; nicotinic acetylcholine receptors
Galantamine-CR	Galantamine-CR	Massachusetts General Hospital	marketed	Cholinesterase inhibitor with nicotinic receptor allosteric modulator	Acetylcholinesterase; nicotinic acetylcholine receptors
Placebo/Galantamine (Reminyl®)	Placebo/Galantamine (Reminyl®)	Ludwig-Maximilians - University of Munich	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase; nicotinic acetylcholine receptors
Extended-release galantamine hydrobromide	Extended-release galantamine hydrobromide	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Cholinesterase inhibitor	Acetylcholinesterase; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Acetylcholinesterase inhibitor with nicotinic receptor modulation class)

Janssen-Cilag Pty Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Galantamine (Reminyl) — Competitive Intelligence Brief. https://druglandscape.com/ci/galantamine-reminyl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab